Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 15/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396844 | 0.85 | AR (0.56) | ARGLAPOLBGAATSHR | |
| SCHEMBL110567 | 0.85 | AR (0.56) | ARGLAPOLBGAATSHR | |
| SCHEMBL1772784 | 0.85 | KDM4E (0.52) | KDM4EUSP2ALDH1A1ARGLA | |
| SCHEMBL15320326 | 0.81 | AR (0.45) | KDM4EUSP2ALDH1A1ARGLA | |
| SCHEMBL22401219 | 0.81 | KDM4E (0.49) | KDM4EUSP2ALDH1A1AR | |
| SCHEMBL15319977 | 0.81 | AR (0.45) | KDM4EUSP2ALDH1A1ARGLA | |
| Hydrochloric Acid SCHEMBL28405816 | 0.80 | KDM4E (0.47) | KDM4EUSP2ALDH1A1AR | |
| SCHEMBL15320186 | 0.76 | AR (0.41) | KDM4EUSP2ALDH1A1ARGLA | |
| SCHEMBL397540 | 0.73 | KDM4E (0.52) | KDM4EUSP2ALDH1A1ARGLA | |
| SCHEMBL30279017 | 0.73 | KDM4E (0.52) | KDM4EUSP2ALDH1A1ARGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2834216-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Catylix Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013152170-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | KDM4E 551/4885USP2 1901/4885ALDH1A1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.